Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor

Pier Paolo Sainaghi1, Luigi Castello, Luca Bergamasco

  • 1Department of Medical Sciences, Università del Piemonte Orientale "A. Avogadro," Novara, Italy.

Insights

Gas6 protein activates the Axl receptor tyrosine kinase, promoting mitogenic effects in prostate cancer cells. This Gas6/Axl interaction, particularly MEK phosphorylation, may drive prostate cancer progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Axl receptor tyrosine kinase is implicated in various malignancies, but its precise role remains complex and not fully understood.
  • Gas6, the ligand for Axl, is a protein known to exert mitogenic effects on normal cell lines.
  • Axl expression is detected in primary prostate carcinoma and associated cell lines like PC-3 and DU 145.

Purpose of the Study:

  • To investigate the role of Gas6/Axl interaction in driving mitogenic activity in undifferentiated, metastatic human prostate cancer cell lines.
  • To elucidate the downstream signaling pathways affected by Gas6/Axl activation in prostate cancer.

Main Methods:

  • Utilized prostate cancer cell lines (PC-3, DU 145) expressing Axl receptor.
  • Assessed the mitogenic effects of Gas6 stimulation.
  • Analyzed downstream signaling by measuring phosphorylation of AKT and MAPK pathways, specifically focusing on MEK.

Main Results:

  • Demonstrated a Gas6-dependent mitogenic effect in Axl-expressing prostate cancer cells.
  • Observed that the mitogenic effect correlated with Axl expression levels.
  • Identified AKT and MAPK phosphorylation, with MEK phosphorylation being crucial for the growth signaling.

Conclusions:

  • Axl receptor tyrosine kinase and its ligand Gas6 play a significant role in promoting prostate cancer cell proliferation.
  • Gas6/Axl signaling, through MEK phosphorylation, appears to be a key driver of prostate cancer progression.
  • Targeting the Gas6/Axl pathway could represent a potential therapeutic strategy for prostate cancer.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...